Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy

Chronological aging as well as biological aging accelerated by various pathologies such as diabetes and obesity contribute to cardiovascular aging, and structural and functional tissue damage of the heart and vasculature. Cardiovascular aging in humans is characterized by structural pathologic remod...

Full description

Bibliographic Details
Main Authors: Lakshmi Pulakat, Howard H. Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00774/full
id doaj-fd02989f6d564c1e998f6965d51081d9
record_format Article
spelling doaj-fd02989f6d564c1e998f6965d51081d92020-11-25T03:15:11ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-05-011110.3389/fphar.2020.00774549988Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced AutophagyLakshmi Pulakat0Lakshmi Pulakat1Howard H. Chen2Howard H. Chen3Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United StatesDepartment of Medicine, Tufts University School of Medicine, Boston, MA, United StatesMolecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, United StatesDepartment of Medicine, Tufts University School of Medicine, Boston, MA, United StatesChronological aging as well as biological aging accelerated by various pathologies such as diabetes and obesity contribute to cardiovascular aging, and structural and functional tissue damage of the heart and vasculature. Cardiovascular aging in humans is characterized by structural pathologic remodeling including cardiac and vascular fibrosis, hypertrophy, stiffness, micro- and macro-circulatory impairment, left ventricular diastolic dysfunction precipitating heart failure with either reduced or preserved ejection fraction, and cardiovascular cell death. Cellular senescence, an important hallmark of aging, is a critical factor that impairs repair and regeneration of damaged cells in cardiovascular tissues whereas autophagy, an intracellular catabolic process is an essential inherent mechanism that removes senescent cells throughout life time in all tissues. Several recent reviews have highlighted the fact that all longevity treatment paradigms to mitigate progression of aging-related pathologies converge in induction of autophagy, activation of AMP kinase (AMPK) and Sirtuin pathway, and inhibition of mechanistic target of rapamycin (mTOR). These longevity treatments include health style changes such as caloric restriction, and drug treatments using rapamycin, the first FDA-approved longevity drug, as well as other experimental longevity drugs such as metformin, rapamycin, aspirin, and resveratrol. However, in the heart tissue, autophagy induction has to be tightly regulated since evidence show excessive autophagy results in cardiomyopathy and heart failure. Here we discuss emerging evidence for microRNA-mediated tight regulation of autophagy in the heart in response to treatment with rapamycin, and novel approaches to monitor autophagy progression in a temporal manner to diagnose and regulate autophagy induction by longevity treatments.https://www.frontiersin.org/article/10.3389/fphar.2020.00774/fullcardiovascularagingsenescenceautophagymicroRNAlongevity drugs
collection DOAJ
language English
format Article
sources DOAJ
author Lakshmi Pulakat
Lakshmi Pulakat
Howard H. Chen
Howard H. Chen
spellingShingle Lakshmi Pulakat
Lakshmi Pulakat
Howard H. Chen
Howard H. Chen
Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
Frontiers in Pharmacology
cardiovascular
aging
senescence
autophagy
microRNA
longevity drugs
author_facet Lakshmi Pulakat
Lakshmi Pulakat
Howard H. Chen
Howard H. Chen
author_sort Lakshmi Pulakat
title Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
title_short Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
title_full Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
title_fullStr Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
title_full_unstemmed Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy
title_sort pro-senescence and anti-senescence mechanisms of cardiovascular aging: cardiac microrna regulation of longevity drug-induced autophagy
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-05-01
description Chronological aging as well as biological aging accelerated by various pathologies such as diabetes and obesity contribute to cardiovascular aging, and structural and functional tissue damage of the heart and vasculature. Cardiovascular aging in humans is characterized by structural pathologic remodeling including cardiac and vascular fibrosis, hypertrophy, stiffness, micro- and macro-circulatory impairment, left ventricular diastolic dysfunction precipitating heart failure with either reduced or preserved ejection fraction, and cardiovascular cell death. Cellular senescence, an important hallmark of aging, is a critical factor that impairs repair and regeneration of damaged cells in cardiovascular tissues whereas autophagy, an intracellular catabolic process is an essential inherent mechanism that removes senescent cells throughout life time in all tissues. Several recent reviews have highlighted the fact that all longevity treatment paradigms to mitigate progression of aging-related pathologies converge in induction of autophagy, activation of AMP kinase (AMPK) and Sirtuin pathway, and inhibition of mechanistic target of rapamycin (mTOR). These longevity treatments include health style changes such as caloric restriction, and drug treatments using rapamycin, the first FDA-approved longevity drug, as well as other experimental longevity drugs such as metformin, rapamycin, aspirin, and resveratrol. However, in the heart tissue, autophagy induction has to be tightly regulated since evidence show excessive autophagy results in cardiomyopathy and heart failure. Here we discuss emerging evidence for microRNA-mediated tight regulation of autophagy in the heart in response to treatment with rapamycin, and novel approaches to monitor autophagy progression in a temporal manner to diagnose and regulate autophagy induction by longevity treatments.
topic cardiovascular
aging
senescence
autophagy
microRNA
longevity drugs
url https://www.frontiersin.org/article/10.3389/fphar.2020.00774/full
work_keys_str_mv AT lakshmipulakat prosenescenceandantisenescencemechanismsofcardiovascularagingcardiacmicrornaregulationoflongevitydruginducedautophagy
AT lakshmipulakat prosenescenceandantisenescencemechanismsofcardiovascularagingcardiacmicrornaregulationoflongevitydruginducedautophagy
AT howardhchen prosenescenceandantisenescencemechanismsofcardiovascularagingcardiacmicrornaregulationoflongevitydruginducedautophagy
AT howardhchen prosenescenceandantisenescencemechanismsofcardiovascularagingcardiacmicrornaregulationoflongevitydruginducedautophagy
_version_ 1724640062251991040